Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

Core Insights - Ocugen's shares fell by 8.6% following the announcement of 12-month data from the phase II ArMaDa study for its gene therapy OCU410, aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) [1][4][7] Study Results - The phase II ArMaDa study indicated that the optimal (medium) dose of OCU410 resulted in a 31% reduction in lesion growth compared to the control group, which is lower than the 46% reduction reported in preliminary data [2][3][7] - Earlier data from the phase II study showed a 46% reduction in lesion growth at 12 months across medium- and high-dose groups, with the medium dose achieving a 54% reduction compared to the control [3] Future Plans - Ocugen plans to initiate a phase III registrational study for OCU410 in Q3 2026, with the medium dose being the optimal dose for this development [4] Market Context - Approximately 2-3 million individuals in the U.S. and Europe are affected by GA, with only one treatment currently available in the U.S. that targets a single aspect of the disease [8] - In Europe, there are no approved treatments for GA, positioning OCU410 as a potential multi-faceted therapy for the condition [8] Pipeline Developments - Ocugen is advancing its gene therapy programs for retinal diseases, including OCU400 in phase III for retinitis pigmentosa and OCU410ST in phase II/III for Stargardt disease [9] - Enrollment for the phase III liMeliGhT study on OCU400 has been completed, with top-line data expected in Q1 2027 [10] - OCU410ST is being developed as a one-time gene therapy for Stargardt disease, with interim data from the ongoing pivotal study expected in Q3 2026 [11]